论文部分内容阅读
目的：探讨扩增的脐血ＣＤ３４细胞体内造血功能。方法：ＦＬＴ３ 配体联合血小板生成素体外培养脐血ＣＤ＋３４细胞２～３ 周后移植ＳＣＩＤ鼠，采用ＦＣＭ 检测ＳＣＩＤ鼠骨髓、外周血、脾脏中的人类ＣＤ４５、ＣＤ３、ＣＤ１９抗原。结果：脐血ＣＤ＋３４细胞扩增１０～３７ 倍，移植６．６×１０４～６．９×１０５ 脐血ＣＤ＋３４细胞于ＳＣＩＤ鼠，６ 周后１０ 只ＳＣＩＤ鼠骨髓中均检测到人类ＣＤ４５抗原（０．２％ ～４．０％ ），６ 只ＳＣＩＤ鼠外周血、脾脏中检测到人类ＣＤ３ 抗原（０．１％ ～２．３％ ），３ 只ＳＣＩＤ鼠中外周血、脾脏中检测到人类ＣＤ１９抗原（０．３％ ～１．３％ ）。结论：ＦＬＴ３ 配体联合血小板生成素体外扩增的脐血ＣＤ＋３４细胞能重建ＳＣＩＤ鼠人类免疫功能。
Objective: To investigate the hematopoietic function of expanded cord blood CD34 cells in vivo. Methods: FLT3 ligand and thrombopoietin were cultured in cord blood CD34 cells in vitro for 2-3 weeks and SCID mice were transplanted. The human CD45, CD3 and CD19 antigens in bone marrow, peripheral blood and spleen of SCID mice were detected by FCM. Results: CD34 + cells were expanded by 10- to 37-fold. Cord blood CD34 + cells were transplanted in SCID mice from 6.6 × 104 to 6.9 × 105 cells. Six weeks later, human CD45 antigen (0 .2% -4.0%). Human CD3 antigen (0.1% -2.3%) was detected in the peripheral blood and spleen of 6 SCID mice. Human CD19 was detected in peripheral blood and spleen of 3 SCID mice Antigen (0.3% ~ 1.3%). Conclusion: FLT3 ligand combined with thrombopoietin in vitro expanded cord blood CD + 34 cells can reconstruct human immune function in SCID mice.